The MYNX CONTROL™ VENOUS Vascular Closure Device is now FDA approved! We're bringing the proven technology of the MYNX family of products to mid-bore venous puncture sites, including electrophysiology procedures. The MYNX CONTROL™ VENOUS VCD expands the Cordis portfolio of extravascular closure devices designed to deliver predictable deployment and ease of use. Leveraging GRIP TECHNOLOGY™, based on hydrophilic, bioinert polyethylene glycol (PEG), the MYNX CONTROL™ VENOUS VCD sealant resorbs 3x faster than collagen-based sealants and provides the quickest time to hemostasis of any venous closure device on the market. #CordisGoBeyond #vascularclosuredevice #venous #electrophysiology https://lnkd.in/eQCtYAfh
About us
With more than a 60-year history of pioneering products to treat millions of patients, Cordis is a worldwide leader in the development and manufacturing of interventional cardiovascular technology. Cordis established a legacy of high-quality and minimally-invasive cardiovascular products; and has built a robust global footprint with operations in more than 60 countries around the world. As from August 2, 2021, Cordis is a standalone company, and is committed to investing $300 million to accelerate innovation in its broad product portfolio. Building on our storied brand, we are unleashing our potential to be a $10 billion leader bringing new technology to the market through bold action at speed.
- Website
-
https://www.cordis.com/en_us.html
External link for Cordis
- Industry
- Medical Equipment Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Miami Lakes, FL
- Type
- Privately Held
Locations
-
Primary
14201 Northwest 60th Avenue
Miami Lakes, FL 33014, US
-
Cahir Road Cashel
Tipperary, E25 RC92 , IE
Employees at Cordis
-
Victor Guerra
Senior Engineering Consultant at Cordis
-
Hervé Cantave,PE, PMP, CSSBB
Sr Principal Engineer at Cordis Corp.
-
Christophe Constantin
Head of Transformation Emerging Markets at Cordis, Non-Executive Director at Toxeos, member of the Investment Committee at the Picard Angst Medtech…
-
Mark Rathbone
Senior Director Emerging Markets Medical Solutions
Updates
-
Today is Juneteenth! #Cordis #CordisGoBeyond
-
-
🚨 Last week the SELUTION SFA Japan Study 24-month results were presented by Dr. Osamu Iida @ JET Japan with positive results, confirming sustained benefits of SELUTION SLR TM (sustained limus release) Drug-Eluting Balloon in complex patients. We invite you to read the full press release here: https://lnkd.in/eRrpBz2z To learn more about this and other drug-eluting balloon studies: https://lnkd.in/eEu9iUgb UNITED STATES: APPROVED FOR INVESTIGATIVE USE ONLY, NOT AVAILABLE FOR COMMERCIAL SALE. #CordisGoBeyond #SELUTIONSLR #DEB #SFA #JETJapan2024
Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients
prnewswire.com
-
🚀 Go Beyond: Redefining Innovation at Cordis🚀 Cordis is going beyond developing innovative products to build innovation into all we do. This week we were profiled for our embrace of a groundbreaking model for innovation, published in Harvard Business Review: "The Middle Path to Innovation" by Regina Herzlinger, Duke Rohlen, Ben Creo, and Will Kynes. The Growth Driver Model, developed in partnership with Ajax Health and leading investment firms Hellman & Friedman and KKR, is transforming our approach to innovation, accelerating our development of a wider range of innovations. This is our commitment to be the heart of innovation to transform cardiovascular care in action! https://lnkd.in/eM_iACYf #CordisGoBeyond #Innovation #GrowthDriver #HBR
The Middle Path to Innovation
hbr.org
-
🚨 Attending JET Japan? 🚨 Don’t miss the late breaking clinical trial session on Friday, June 14th from 8-9 am (Japan Standard Time) in Hall A -3F Main Hall. Dr. Osamu Iida will present the 24-month results from SELUTION SFA Japan trial -Safety and Efficacy of a Novel Sirolimus-Coated Balloon for the Treatment of Femoropopliteal Lesions in Japanese Population. Read about the 1yr. data published in JACC: Cardiovascular Interventions - A Novel Sirolimus-Coated Balloon for the Treatment of Femoropopliteal Lesions: The SELUTION SFA Japan Trial https://lnkd.in/ew3R6qZV UNITED STATES: APPROVED FOR INVESTIGATIVE USE ONLY, NOT AVAILABLE FOR COMMERCIAL SALE. #CordisGoBeyond #DEB #SFA #JETJapan2024
-
-
Happy Pride Month! #Pride2024
-
-
🚀Key takeaways on the European SELUTION DeNovo trial presented at EuroPCR 🚀 The largest randomized clinical trial comparing a treatment strategy of drug-eluting balloons (DEB) to limus drug-eluting stents (DES) implantation for target vessel failure (TVF) is making significant strides: 🔹 Enrolled over 2800 out of 3326 patients with no safety signals raised by independent data safety monitoring board (when first 2119 patients were assessed). First 1000 patients: 🔹 Reflects routine PCI practice, with over 56% of patients having a reference vessel diameter of ≥ 3.0 mm. 🔹 Bail-out stent rate has decreased from 21% to 15.2% as centers gain more experience, even with increasing lesion and patient complexity. We are proud to be at the forefront of this groundbreaking study, designed to change medical practice of de-novo coronary artery disease treatment. Check out the interview from Dr. simon eccleshall sharing with us the highlights of his presentation - https://lnkd.in/exRHNX3S Stay tuned for more updates! 🌟 #EuroPCR #ClinicalTrials #SELUTIONDeNovo #InterventionalCardiology #PCI #CordisGoBeyond #GoBeyondMetal #DEB #DCB #DES UNITED STATES: APPROVED FOR INVESTIGATIVE USE ONLY, NOT AVAILABLE FOR COMMERCIAL SALE.
Dr. Simon Eccleshall, UK
cordis.com
-
Attending NCVH in New Orleans? The Cordis team is onsite to welcome you at booth# 105. Stop by and hear about what's new at Cordis! #CordisGoBeyond #NCVH2024
-
-
Cordis reposted this
A little belated but we recently welcomed Tony Kim to Cordis working on our transformation team and as part of our newly launched leadership development program (more to come here...). He is already moving the needle on some of the big, strategic problems we are trying to solve. I'm still looking for more former consultants to join our team. We're focused on the most critical questions facing Cordis, and these roles have a ton of day-to-day executive exposure. Reach out to me if you want to hear more.
-
Cordis is excited to welcome you to our Innovation room at #LINC2024 in Leipzig, Don't miss the opportunity to register and meet the experts: - Prof. Martin Werner on #radial access - Prof. Dr. Christos Rammos, MHBA and Dr Bruno Migliara on #CLTI & #DEB - Dr. Bruno Migliara on #catheterization More info & registration: https://lnkd.in/eihHNs35 #AdvancingEducation #PeripheralInterventions #CLIFighters #PeripheralInterventions #PAD #CLTI #DCB #DEB #RespectTheRadial #PeripheralArteryDisease #InterventionalRadiology #RadialFirst